

0040-4039(94)01101-X


SYNTHESIS OF EPIBATIDINE

Kazimir Sestanji*, Edward Melenski and Ivo Jirkovsky
 Wyeth-Ayerst Research, Princeton, NJ 08540

Abstract: A total synthesis of racemic epibatidine, a natural product with analgesic activity, is described. Distinctly different from the previously published routes it starts from simple, known precursors, to provide the alkaloid in six steps.

Epibatidine (**1**), one of the numerous alkaloids isolated from the skin of poisonous frog *Epipedobates tricolor*, is pharmacologically interesting for its strong analgesic action apparently effected by a non-opioid mechanism.¹


The scarcity of the natural material has prompted us to investigate a synthetic approach that would secure a supply of **1** and its derivatives in quantities sufficient for the biological testing. Our strategy was to close the nitrogen bridge of the 7-azabicyclo[2.2.1]heptane ring after the rest of the skeleton had been assembled (including an easily convertible precursor of the chloropyridine moiety) as shown in the retrosynthetic scheme:



Several total syntheses of epibatidine which are conceptually different from our own, have been published so far.¹⁴ Two of them^{2,3} use Diels-Alder type reactions to construct the molecular framework with subsequent removal of activating groups (initially needed to achieve a reasonable rate of cycloaddition). The first published synthesis^{2a} employed the diene addition at a very early stage and required 16 steps for completion. In the second synthesis,³ the entire system was assembled in one step but it suffered from an unfavorable ratio of the stereoisomers (endo/exo 2:1) as a result of an unavoidable double bond reduction at the critical stereocenter. The third synthesis⁴ used a 7-azabicyclo[2.2.1]heptane derivative as a starting material and then introduced the chloropyridine substituent. This process also produced the exo isomer as a minor component only (1:4 ratio). An epimerisation step was then needed for an apparently successful endo to exo conversion.¹⁶

We have employed known 2-methoxy-5-lithiopyridine^{5a} and 4-hydroxy-2-cyclohexenone⁶ as starting materials. The lithiopyridine was converted to a "higher order" lithiocuprate **2** and the hydroxyl of the hydroxyketone was protected with trimethylsilyl group (**3**). The essential requirement for the successful preparation of **2** and conjugate addition of **2** to **3** was to prepare 2-methoxy-5-lithiopyridine in diethyl ether as all attempts to work with tetrahydrofuran failed.^{5b} That problem might have thwarted the conjugate addition in an attempt to shorten the first mentioned, published synthesis.^{2b}

We obtained the ketone **4** after a column chromatography on silica gel in 60% yield as 9:1 (trans/cis) mixture of isomers.⁷ The proper stereochemistry for two out of three centers was thus introduced in the first step. The ketone **4** was then converted to its oxime **5** (70%, crude, mixture of syn- and anti-)⁸ which furnished a mixture of tosylamino-isomers **6** upon reduction with Ni/Al alloy and tosylation⁹ in 60% yield. Without separation of the resulting stereoisomers (1:1 ratio), the mixture was subjected to Mitsunobu conditions (DEAD, PPh₃) giving the fully assembled ring system **7**¹⁰ in 88% yield (based on the correct isomer). Removal of the tosyl group with sodium amalgam and conversion to dihydrochloride **8**¹¹ (40%) followed by the transformation of methoxy group to the chloro- substituent with POCl₃/PCl₅ completed the synthesis of racemic **1**.¹²



a) -35° to 20° , Et₂O/THF, NH₄Cl; b) NH₂OH.HCl, NaOAc, MeOH; c) Ni/Al, NaOH, EtOH; d) TsCl, NaHCO₃, THF/H₂O; e) DEAD, PPh₃, THF; f) Na/Hg, Na₂HPO₄, Et₂O/HCl; g) POCl₃/PCl₅, Et₂O/HCl.

Yields of the last step were erratic and seemingly dependent on conditions of the work-up.¹⁵ The best yield obtained in one case was 40% (crude) by heating **8** at 105-110° for 3.5 days with 10 molar equivalents of pentachloride and enough POCl₃ to dissolve the starting material (after five days no **1** could be isolated).

The merits of the synthesis are two crucial steps: a) successful preparation of the pyridyl lithiocuprate **2** and conjugate addition to the ketone **3**; b) novel method to prepare 7-azabicyclo[2.2.1]heptane ring system by Mitsunobu reaction of 4-tosylaminocyclohexanols (reported so far only in formation of monocyclic systems from acyclic tosylaminoalcohols¹³).

Acknowledgements:

The authors are indebted to Dr. N. Jensen for his interest. We would also like to thank Professors D. Curran, S. Burke and T. Macdonald as well as Dr. Wrobel for helpful discussions. Spectral data were provided by Mr. B. Hofmann and his staff; analytical and preparative HPLC was conducted by Dr. M. Kagan and his group; the camera-ready manuscript was prepared by Ms. Cheryl Delfino.

References and notes

1. Spande, T.F. et al. *J. Am. Chem. Soc.* **1992**, *114*, 3475.
2. a) Broka, C.A. *Tetrahedron Letters* **1993**, *34*, 3251; b) *ibid.* Ref. 8. (the problem could have also arisen if a "higher order" cyanocuprate was not employed in the conjugate addition).
3. Huang, D.F. and Shen, T.Y. *Tetrahedron Letters* **1993**, *34*, 4477 and references herein.
4. Fletcher, S.R. et al. *J. Chem. Soc., Chem. Commun.* **1993**, 1216.
5. a) Kompis, I. et al. *Eur. J. Med. Chem.* **1977**, *12*, 531; b) In order to avoid possible solubility problems by mixing solvents an attempt was made at first to prepare 2-methoxy-5-lithiopyridine in THF since the thiophene lithiocyanocuprate, necessary for the complex formation was commercially available as a THF solution. However, it was established later that once the lithiopyridine had been prepared in ether as an insoluble precipitate, the addition of thiophene lithiocuprate- THF solution led to formation of desired **2** (the presence of THF had obviously no negative effect at that stage); Bell, A.S. et al. *Synthesis* **1987**, 843, claim a successful preparation of several lithiopyridines in THF.
6. Danishefsky, S.J. and Simoneau, B. *J. Am. Chem. Soc.* **1989**, *111*, 2599.
7. **4**: MS (EI) m/z 293 (M⁺), 278, 265. ¹H NMR (CDCl₃) δ 8.00 (d, 1H, J=2.5 Hz), 7.40 (dd, 1H, J=2.5 Hz, 8.5 Hz), 6.72 (d, 1H, J=8.5 Hz), 3.91 (m, 4H), 3.02 (td, J=14.7 Hz, 3 Hz, 1H), 2.65-2.40 (m, 4H), 2.06 (m, 1H), 1.85 (m, 1H), -0.1 (s, 9H).

8. **5:** MS (DEI) m/z 236
9. **6:** MS (FAB) m/z 375 (M-H)⁻. ¹H NMR showed duplex chemical shifts of several characteristic protons designating a presence of two stereoisomers. HPLC revealed a 1:1 mixture of isomers.
10. **7:** MS (EI) m/z 358 (M⁺). ¹H NMR (CDCl₃) δ 7.90 (d, J=2.5, 1H), 7.78 (d, J=8.3, 2H), 7.52 (dd, J=2.5, 8.7, 1H), 7.28 (d, J=8.3, 2H), 6.59 (d, J=8.7, 1H), 4.32 (t, J=4, 1H), 4.05 (d, J=3.5, 1H), 3.88 (s, 3H), 2.76 (dd, J=9, 5, 1H), 2.42 (s, 3H), 1.94 (dd, J=9, 12, 1H), 1.86-1.74 (broad, 3H), 1.52 (m, 2H).
11. **8:** MS (EI) m/z 204 (M⁺). ¹H NMR (DMSO) δ 8.95 (br, 1H), 8.40 (br, 1H), 8.14 (d, J=2.7, 1H), 7.72 (dd, J=2.7, 8.5, 1H), 6.81 (d, J=8.5, 1H), 4.36 (br, 1H), 4.22 (br, 1H), 3.83 (s, 3H), 3.24 (m, 1H), 2.25 (m, 1H), 1.95-1.79 (br, 4H), 1.72-1.66 (br, 1H).
12. **1 (oxalate):** MS (EI) m/z 208 (M⁺). ¹H NMR (DMSO) δ 8.40 (d, J=2.4, 1H), 7.84 (dd, J=8.3, 2.6, 1H), 7.48 (d, J=8.1, 1H), 4.40 (s, 1H), 4.20 (s, 1H), 3.30 (dd, J=9.4, 6.0, 1H), 2.27 (dd, J=9.4, 12.9, 1H), 1.95-1.60 (m, 5H).
13. Henry, J.R. et al. *Tetrahedron Letters* **1989**, *30*, 5709
14. After completion of this work a stereocontrolled synthesis of optically active epibatidine by E. J. Corey et al. (*J. Org. Chem.* **1993**, *58*, 5600) and a short elegant synthesis of racemic **1** by S. C. Clayton and A. C. Regan (*Tetrahedron Lett.* **1993**, *34*, 7493) have been published both also distinctly different from our own.
15. The excess of POCl₃ was evaporated, conc. HCl added to the residue, the mixture heated to boiling point, cooled, alkalized (pH~10) and extracted with ether.
16. Note added in proof: Szantay, C. et al. *Tetrahedron Letters* **1994**, *35*, 3171, described a new synthesis of epibatidine which also relied on the epimerisation in the last step.

(Received in USA 27 April 1994; revised 3 June 1994; accepted 7 June 1994)